CytoSorbents Corporation (CTSO)

[ranchhand71]

Item 1.02 Termination of Material Definitive Agreement.


On July 27, 2021, CytoSorbents Corporation (the “Company”) delivered to Jefferies LLC (“Jefferies”) and B. Riley FBR, Inc. (“B. Riley” and together with Jefferies, the “Banks”) written notice of termination (the “Termination Notice”) of the Open Market Sale AgreementSM, dated July 9, 2019, by and among the Company, Jefferies, and B. Riley (as amended to date, the “Sales Agreement”). In accordance with Section 7(b) thereof, the Sales Agreement will terminate on August 3, 2021, ten (10) trading days after the delivery of the Termination Notice. The Company is terminating the Sales Agreement due to the anticipated effectiveness of its new shelf registration statement on Form S-3 (File No. 333-257910). As provided in the Sales Agreement, the Sales Agreement will terminate without liability of any party to any other party, except that certain provisions of the Sales Agreement identified therein shall remain in full force and effect notwithstanding the termination.



Pursuant to the Sales Agreement, the Company offered and sold, from time to time through the Banks, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In the aggregate, the Company sold 4,301,869 shares of Common Stock pursuant to the Sales Agreement at an average selling price of $6.53 per share, generating net proceeds of approximately $27.2 million. The Company paid the Banks a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and provided the Banks with customary indemnification rights.